Monoclonal Antibody Targeting Interleukin-6 Achieves Sustained Reductions in Inflammation Biomarkers Through Six Months

Phase 2 TRANQUILITY trial results presented by Mount Sinai investigator support further evaluation of pacibekitug in cardiovascular disease